InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,815.03
(
0.61%
)
US TECH 100
19,700.00
(
-0.02%
)
Dow Jones
42,863.86
(
0.97%
)
Brent Oil
78.70
(
0.00%
)
Bitcoin
62,695.09
(
-0.78%
)
Post# of 253355
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

dav1234

Send PM Follow Ignore
Followers 97
Posts 92809
Boards Moderated 4
Alias Born 10/29/2007

dav1234

Re: dav1234 post# 143188

Monday, 06/04/2012 1:14:47 PM

Monday, June 04, 2012 1:14:47 PM

Post# of 253355
Baird says Dendreon's (DNDN -8.5%) Provenge may have a difficult road to commercial acceptance especially after this weekend's ASCO meeting in which both Bristol Myers (BMY flat) and Medivation (MDVN -2%) published impressive trial results for their prostate drugs. The firm loweres its 2014 and 2015 estimates for Provenge and said the drug may have trouble remaining relevant
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up